Receptor News and Research

RSS

Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global public health challenge with rapidly rising prevalence, especially in China. Despite advances in treatment, the underlying molecular mechanisms remain incompletely understood. A new research article published in the Chinese Medical Journal on March 16, 2026, provides critical insights into the role of exosomal microRNAs (miRNAs) in MASLD pathogenesis.

17 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

How the immune system may influence Alzheimer’s, Parkinson’s, and related diseases

This review argues that neurodegeneration is shaped not only by toxic protein buildup but also by immune signaling, with microglia and T cells able to either protect the brain or worsen damage depending on context. It also highlights aging, head injury, and viral infection as major forces that reshape CNS immunity and may influence disease progression and future treatment strategies.

16 Apr 2026

Researchers discover how stress signals weaken the aging immune system

As we age, our ability to maintain healthy blood and a strong immune system gradually declines, largely because hematopoietic stem cells (HSCs), the cells responsible for producing all blood cell types, begin to lose their effectiveness. Normally, HSCs can both self-renew and generate a balanced mix of blood cells, but over time they produce fewer new cells, favor certain cells such as myeloid cells over lymphoid cells, and struggle to support a robust immune response.

16 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).

From Bio-Rad Laboratories 15 Apr 2026

Study identifies new genes linked to severe pregnancy sickness

The USC research team that recently identified the hormone-encoding gene GDF15 as a key driver of pregnancy sickness has identified 9 additional genes linked to its most severe form, hyperemesis gravidarum (HG).

14 Apr 2026

SARS-CoV-2 rarely reaches first-trimester placentas but still disrupts early pregnancy immunity

Researchers analyzing 761 first-trimester pregnancies found that SARS-CoV-2 was rarely detected in placental tissues, suggesting in utero transmission early in pregnancy is uncommon. However, maternal infection was linked to immune dysregulation at the maternal-fetal interface, altered trophoblast signaling, and inflammatory changes that could affect placental development.

14 Apr 2026

Parents’ intake of sugar substitutes may influence offspring gut biology, study finds

A mouse study in Frontiers in Nutrition found that parental sucralose and stevia intake altered gut microbiota, short-chain fatty acids, and gene expression across generations, with sucralose showing the stronger and more persistent effects. The changes were transmitted to offspring not directly exposed to the sweeteners, although several effects were attenuated by the F2 generation.

13 Apr 2026

Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40 %, in adults in the UK.

From Bayer PLC 13 Apr 2026

Higher mortality risk in IBS patients using antidepressants

Research indicates that antidepressant use in IBS is linked to a 35% higher risk of all-cause mortality, highlighting safety issues with long-term treatment.

13 Apr 2026

Genetic variants may reduce effectiveness of popular diabetes drugs

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

12 Apr 2026

Enriched environments improve stroke recovery and reduce brain inflammation

Stroke is one of the leading causes of death worldwide. Its recovery is often challenging as most of the stroke survivors remain chronically disabled, with motor deficits affecting a significant percentage of patients.

11 Apr 2026

Nanomedicine offers targeted solutions for breast cancer treatment

Breast cancer (BCA) is one of the most common cancers worldwide, with high mortality and morbidity in women.

10 Apr 2026

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

10 Apr 2026

Extracellular vesicles from menstrual blood cells show potential to stimulate cartilage repair

New research by an interdisciplinary team in Lithuania has revealed a promising and unconventional approach to cartilage regeneration.

10 Apr 2026

GLP-1 and dual GLP-1 / GIP drugs help lose body fat while preserving lean mass

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across 6 months of treatment.

10 Apr 2026

Large US study finds never-married adults face higher risk for most major cancers

A large US population-based study found that never-married adults had higher cancer incidence than ever-married adults across most cancer types, with the largest disparities seen in older adults and in Black men. The pattern was especially strong for HPV-related, tobacco-related, and several reproductive cancers, suggesting marital status may act as an important social marker of cancer risk.

9 Apr 2026

Study finds nutritional risks in users of GLP-1 drugs

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.

9 Apr 2026

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

A large 23andMe-based GWAS found that common variants in GLP1R and GIPR help explain why some people lose more weight or experience more nausea and vomiting on GLP-1 drugs. The findings suggest genetics may eventually help predict who responds best to semaglutide or tirzepatide and who is more likely to develop side effects.

9 Apr 2026

Receptor News and Research

Circulating exosomal microRNAs offer a non-invasive biomarker for MASLD

Why AI is becoming a powerful tool in cancer drug discovery

How the immune system may influence Alzheimer’s, Parkinson’s, and related diseases

Researchers discover how stress signals weaken the aging immune system

Semaglutide improves liver function independently of weight loss

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Study identifies new genes linked to severe pregnancy sickness

SARS-CoV-2 rarely reaches first-trimester placentas but still disrupts early pregnancy immunity

Parents’ intake of sugar substitutes may influence offspring gut biology, study finds

Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %

Higher mortality risk in IBS patients using antidepressants

Genetic variants may reduce effectiveness of popular diabetes drugs

Enriched environments improve stroke recovery and reduce brain inflammation

Nanomedicine offers targeted solutions for breast cancer treatment

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Extracellular vesicles from menstrual blood cells show potential to stimulate cartilage repair

GLP-1 and dual GLP-1 / GIP drugs help lose body fat while preserving lean mass

Large US study finds never-married adults face higher risk for most major cancers

Study finds nutritional risks in users of GLP-1 drugs

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News